Our STN: BL 125748/0

BLA APPROVAL
June 3, 2022

GlaxoSmithKline Biologicals SA
Attention: Michael P. Schwartz, Ph.D.
1250 South Collegeville Road
Collegeville, PA 19426

Dear Dr. Schwartz:

Please refer to your Biologics License Application (BLA) received June 04, 2021, submitted under section 351(a) of the Public Health Service Act (PHS Act) for Measles, Mumps and Rubella Vaccine, Live.

LICENSING

We have approved your BLA for Measles, Mumps and Rubella Vaccine, Live effective this date. You are hereby authorized to introduce or deliver for introduction into interstate commerce Measles, Mumps and Rubella Vaccine, Live under your existing Department of Health and Human Services U.S. License No. 1617. Measles, Mumps and Rubella Vaccine, Live is indicated for active immunization for the prevention of measles, mumps, and rubella in individuals 12 months of age and older.

The review of this product was associated with the following National Clinical Trial (NCT) numbers: NCT00861744, NCT01621802, NCT02058563, NCT01702428, NCT01681992 and NCT02184572.

MANUFACTURING LOCATIONS

Under this license, you are approved to manufacture the measles and rubella drug substances for Measles, Mumps and Rubella Vaccine, Live at GlaxoSmithKline Biologicals (b) (4) and the mumps drug substance at (b) (4) The final drug product (Lyophilized Antigen Component, Live) will be manufactured, filled, lyophilized, labeled and packaged at (b) (4) GlaxoSmithKline Vaccines, (b) (4) The diluent (Sterile Water Diluent Component) will be manufactured and filled at (b) (4) and labeled and packaged with the lyophilized antigen component at (b) (4) GlaxoSmithKline Vaccines, (b) (4) .

You may label your product with the proprietary name PRIORIX. The vaccine will be supplied in a ten-dose configuration that contains ten single-dose vials of lyophilized antigen component and ten single-dose prefilled, ungraduated syringes of sterile water diluent component.

ADVISORY COMMITTEE

We did not refer your application to the Vaccines and Related Biological Products Advisory Commitee because our review of information submitted in your BLA, including the clinical study design and trial results, did not raise concerns or controversial issues that would have benefited from an advisory committee discussion.

DATING PERIOD

The dating period for the lyophilized antigen component of Measles, Mumps and Rubella Vaccine, Live shall be 24 months from the date of manufacture when stored at +5°C ± 3°C. After unlabeled vials are filled with the vaccine antigen and their contents are lyophilized, the vials can be stored for a maximum storage period of (b) (4) at 2°C - 8°C, allowing the performance of the 100% visual inspection. Following visual inspection, the vials can be stored for an intermediate period of up to (b) (4) . Final labeling and packaging operations for the vials containing lyophilized vaccine antigen are performed when the vials are removed from (b) (4). The date of manufacture shall be defined as the date the vaccine antigen vials are removed from (b) (4) to begin final labeling and packaging operations. The dating period for your measles, mumps and rubella monovalent drug substances shall be (b) (4) when stored at (b) (4) The dating period for the diluent component (Water for Injection) of Measles, Mumps and Rubella Vaccine, Live in the prefilled ungraduated syringes is 60 months from the date of manufacture when stored at +25°C ± 2°C. The date of manufacture shall be defined as the date of filling of the diluent. The expiration date for the packaged product, consisting of lyophilized vaccine antigen component and sterile water diluent component, shall be the earlier expiration date of either component.

COMPARABILITY PROTOCOLS

This approval also includes comparability protocols for (1) the production, qualification and reporting of (b) (4) Rubella Working Virus Seeds to be used in the manufacture of rubella monovalent drug substance and (2) the (b) (4) (i.e., Measles-Mumps-Rubella vaccine lot) to be used in the potency assay by (b) (4) testing procedure for the assay validity purpose only.

Under 21 CFR 601.12(e), approval of a comparability protocol may justify a reduced reporting category for a particular change. In your annual report (21 CFR 601.12(d)), you should report information confirming that the changes meet the requirements specified in your approved comparability protocols. Include the information described in 21 CFR 601.12(d)(3).

FDA LOT RELEASE

Please submit final container samples of the product in final containers together with protocols showing results of all applicable tests. You may not distribute any lots of product until you receive a notification of release from the Director, Center for Biologics Evaluation and Research (CBER).

BIOLOGICAL PRODUCT DEVIATIONS

You must submit reports of biological product deviations under 21 CFR 600.14. You should identify and investigate all manufacturing deviations promptly, including those associated with processing, testing, packaging, labeling, storage, holding and distribution. If the deviation involves a distributed product, may affect the safety, purity, or potency of the product, and meets the other criteria in the regulation, you must submit a report on Form FDA 3486 to the Director, Office of Compliance and Biologics Quality, electronically through the eBPDR web application or at the address below. Links for the instructions on completing the electronic form (eBPDR) may be found on CBER's web site at https://www.fda.gov/vaccines-blood-biologics/report-problem-center-biologics-evaluation-research/biological-product-deviations.

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

MANUFACTURING CHANGES

You must submit information to your BLA for our review and written approval under 21 CFR 601.12 for any changes in, including but not limited to, the manufacturing, testing, packaging or labeling of Measles, Mumps and Rubella Vaccine, Live, or in the manufacturing facilities.

LABELING

We hereby approve the draft content of labeling including the Package Insert submitted under amendment 48, dated June 3, 2022; the draft container labels submitted under amendment 43, dated May 26, 2022; and draft carton label submitted under amendment 46, dated June 1, 2022.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert submitted on

June 3, 2022. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

CARTON AND CONTAINER LABELS

Please electronically submit final printed carton and container labels identical to the container labels submitted on May 26, 2022, and the carton label submitted on June 1, 2022, according to the guidance for industry *Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications* at https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm333969.pdf.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125748, at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71-G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

ADVERSE EVENT REPORTING

You must submit adverse experience reports in accordance with the adverse experience reporting requirements for licensed biological products (21 CFR 600.80), and you must submit distribution reports as described in 21 CFR 600.81. For

information on adverse experience reporting, please refer to the guidance for industry *Providing Submissions in Electronic Format —Postmarketing Safety Reports for Vaccines* at http://www.fda.gov/forindustry/electronicsubmissionsgateway/ucm387293.htm. For information on distribution reporting, please refer to the guidance for industry *Electronic Submission of Lot Distribution Reports* at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Post-MarketActivities/LotReleases/ucm061966.htm.

PEDIATRIC REQUIREMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for children <12 months of age because the product does not represent a meaningful therapeutic benefit over existing therapies for children in this age group and is not likely to be used in a substantial number of children in this age group.

This product is appropriately labeled for use in individuals 12 months of age and older for this indication. Therefore, no additional studies are needed in this pediatric age group.

We note that you have fulfilled the pediatric study requirement for ages 12 months through 16 years for this application.

POST APPROVAL FEEDBACK MEETING

New biological products qualify for a post approval feedback meeting. Such meetings are used to discuss the quality of the application and to evaluate the communication process during drug development and marketing application review. The purpose is to learn from successful aspects of the review process and to identify areas that could benefit from improvement. If you would like to have such a meeting with us, please contact the Regulatory Project Managers for this application.

Sincerely,

For Peter Marks, M.D., Ph.D.
Acting Director
Office of Vaccines Research and Review
Center for Biologics Evaluation and Research